Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.

Adamia S, Reiman T, Crainie M, Mant MJ, Belch AR, Pilarski LM.

Blood. 2005 Jun 15;105(12):4836-44. Epub 2005 Feb 24.

2.

Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.

Kriangkum J, Warkentin A, Belch AR, Pilarski LM.

PLoS One. 2013;8(1):e53469. doi: 10.1371/journal.pone.0053469. Epub 2013 Jan 3. Erratum in: PLoS One. 2013;8(4). doi:10.1371/annotation/9984da27-0e7f-4c7f-bcd3-bef1a4c0be87. Warkinton, Amanda [corrected to Warkentin, Amanda].

3.

Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression.

Adamia S, Kriangkum J, Belch AR, Pilarski LM.

Adv Cancer Res. 2014;123:67-94. doi: 10.1016/B978-0-12-800092-2.00003-4. Review.

PMID:
25081526
4.

Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.

Ghosh A, Kuppusamy H, Pilarski LM.

J Biol Chem. 2009 Jul 10;284(28):18840-50. doi: 10.1074/jbc.M109.013813. Epub 2009 May 18.

6.

Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.

Kuppusamy H, Ogmundsdottir HM, Baigorri E, Warkentin A, Steingrimsdottir H, Haraldsdottir V, Mant MJ, Mackey J, Johnston JB, Adamia S, Belch AR, Pilarski LM.

PLoS One. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691. eCollection 2014.

7.

Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia.

Adamia S, Reichert AA, Kuppusamy H, Kriangkum J, Ghosh A, Hodges JJ, Pilarski PM, Treon SP, Mant MJ, Reiman T, Belch AR, Pilarski LM.

Blood. 2008 Dec 15;112(13):5111-21. doi: 10.1182/blood-2008-02-141770. Epub 2008 Sep 24.

8.

Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets.

Adamia S, Pilarski PM, Belch AR, Pilarski LM.

Curr Cancer Drug Targets. 2013 May;13(4):347-61. Review.

PMID:
23517594
9.

Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia.

Adamia S, Crainie M, Kriangkum J, Mant MJ, Belch AR, Pilarski LM.

Semin Oncol. 2003 Apr;30(2):165-8.

PMID:
12720129
10.

Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia.

Adamia S, Treon SP, Reiman T, Tournilhac O, McQuarrie C, Mant MJ, Belch AR, Pilarski LM.

Clin Lymphoma. 2005 Mar;5(4):253-6.

PMID:
15794859
11.

Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas.

Shigeishi H, Fujimoto S, Hiraoka M, Ono S, Taki M, Ohta K, Higashikawa K, Kamata N.

Int J Oncol. 2009 Jun;34(6):1565-71.

PMID:
19424574
12.
14.

SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.

Taylor BJ, Reiman T, Pittman JA, Keats JJ, de Bruijn DR, Mant MJ, Belch AR, Pilarski LM.

J Immunother. 2005 Nov-Dec;28(6):564-75.

PMID:
16224274
15.

Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells.

de Lange P, Segeren CM, Koper JW, Wiemer E, Sonneveld P, Brinkmann AO, White A, Brogan IJ, de Jong FH, Lamberts SW.

Cancer Res. 2001 May 15;61(10):3937-41.

16.

Alternative splicing of RHAMM gene in chinese gastric cancers and its in vitro regulation.

Li H, Guo L, Li J, Liu N, Liu J.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2000 Oct;17(5):343-7. Chinese.

PMID:
11024216
17.

Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.

Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R, Santo L, Drandi D, Bertola A, Falco P, Cavallo F, Ricca I, De Marco F, Mantoan B, Bode-Lesniewska B, Pagliano G, Francese R, Rocci A, Astolfi M, Compagno M, Mariani S, Godio L, Marino L, Ruggeri M, Omedè P, Palumbo A, Boccadoro M.

Blood. 2005 Jun 15;105(12):4784-91. Epub 2005 Feb 24.

18.

N34S mutation in the SPINK1 gene is not associated with alternative splicing.

Masamune A, Kume K, Takagi Y, Kikuta K, Satoh K, Satoh A, Shimosegawa T.

Pancreas. 2007 May;34(4):423-8.

PMID:
17446841
19.

Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.

Ria R, Todoerti K, Berardi S, Coluccia AM, De Luisi A, Mattioli M, Ronchetti D, Morabito F, Guarini A, Petrucci MT, Dammacco F, Ribatti D, Neri A, Vacca A.

Clin Cancer Res. 2009 Sep 1;15(17):5369-78. doi: 10.1158/1078-0432.CCR-09-0040. Epub 2009 Aug 18.

Supplemental Content

Support Center